Cancer Microbiome Sequencing Market - Industry Size, Share, Growth & Forecast 2027 | UnivDatos

 

The Cancer Microbiome Sequencing Market has been growing on account of various factors including the growing emphasis on the microbiome’s potential in the field of cancer and surging incidences of cancer across the globe. For instance, the number of cancer cases in the US will increase 49% each year, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years, as per the predictions by CDC. This exponential increase in cancer prevalence has created a buzz among biotechnology companies for investing in the development of novel diagnostic tools based on the microbiome that will offer early cancer detection.

The recent COVID-19 pandemic has disrupted the healthcare industry with the emergence of SARS-COV-2 and the huge number of infected patients has significantly impacted the cancer microbiome sequencing market. The lung microbiome was discovered and played a significant role in the formation of immune responses to viral infections impacting COVID-19’s prognosis.
Request Sample Copy of this Report @ https://univdatos.com/get-a-free-sample-form-php/?product_id=18466

According to UnivDatos Market Insights (UMI)’ research report “Global Cancer Microbiome Sequencing Analysis, 2020”, the cancer microbiome sequencing market is projected to grow at a CAGR of around 20% during 2021-27F. Promulgating strategic alliances among industry players for accelerating microbiome research is another prominent factor that is significantly driving the cancer microbiome sequencing market globally. For example, in June 2021, Illumina and Microba Life Sciences came into a partnership to advance their understanding of the human gut microbiome in human health and disease. Illumina’s revolutionary NGS tools and Microba’s high-quality proprietary gut microbiome analysis platform will generate the accurate metagenomic data that researchers require to fuel discoveries.

Based on the application, the market is fragmented into colorectal cancer, cervical cancer, oral cancer, and others. The colorectal cancer segment accounted for a considerable share in 2020 and is anticipated to register a lucrative CAGR during the forecast period owing to the rising incidences of colorectal cancer globally.

Hospitals & Diagnostic Laboratories Segment to Witness Robust growth

Based on end-users, the market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and others. The hospitals & diagnostic laboratories segment had the highest revenue and CAGR growth as the majority of the sequencing test takes place in laboratories for detecting various diseases. However, the academic & research institutes segment is expected to grow significantly in the upcoming years.

Request Sample Copy of this Report @ https://univdatos.com/get-a-free-sample-form-php/?product_id=18466
North America to Grab Lion’s Share, and witnessed Explicit Growth

Based on the region, North America dominated the global cancer microbiome sequencing market in 2020. The region is projected to maintain its dominance during the forecasted period 2021-27 owing to the presence of well-established healthcare infrastructure and the presence of major market players in the region.
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the Cancer Microbiome Sequencing Market include Thermo Fisher Scientific Inc., CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., QIAGEN N.V., Micronoma Inc., Oxford Nanopore Technologies, Zymo Research Corporation, OraSure Technologies, Inc., among others. The players are focused on launching products for gaining customers' traction and expanding their geographical reach to get a competitive edge in the industry.  

provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for cancer microbiome sequencing providers across the Globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on 16 parameters. This will help companies in the formulation of go to Market Strategies and identifying the blue ocean for its offerings.
For More Informative Information, Please Visit Us @ https://univdatos.com/report/cancer-microbiome-sequencing-market/

Market Segmentation:

1.      By Offerings (Products and Services)

2.      By Technology (Next-Generation Sequencing and Polymerase Chain Reaction)

3.      By Application (Colorectal Cancer, Cervical Cancer, Oral Cancer, and Others)

4.      By End-Users (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, and Others)

5.      By Region (North America, Europe, Asia-Pacific, Rest of the World)

6.      By Company (Thermo Fisher Scientific Inc., CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., QIAGEN N.V., Micronoma Inc., Oxford Nanopore Technologies, Zymo Research Corporation, OraSure Technologies, Inc., etc.)

Key questions answered in the study:

1.      What are the current and future trends of the cancer microbiome sequencing industry?

2.      How the industry has been evolving in terms of offerings, application, technology, and end-users?

3.      How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.      What are the key growth drivers and challenges for the cancer microbiome sequencing industry?

5.      What is the customer orientation, purchase behavior, and expectations from cancer microbiome sequencing firms across various regions?

Table of Content –

1 MARKET INTRODUCTION

2 RESEARCH METHODOLOGY OR ASSUMPTION

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL CANCER MICROBIOME SEQUENCING MARKET REVENUE

7 MARKET INSIGHTS BY OFFERINGS

8 MARKET INSIGHTS BY TECHNOLOGY

9 MARKET INSIGHTS BY APPLICATION

10 MARKET INSIGHTS BY END-USERS

11 MARKET INSIGHTS BY REGION

12 CANCER MICROBIOME SEQUENCING MARKET DYNAMICS

13 CANCER MICROBIOME SEQUENCING MARKET OPPORTUNITIES

14 CANCER MICROBIOME SEQUENCING MARKET TRENDS & INSIGHTS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

19 COMPANY PROFILED

20 DISCLAIMER

Browse Other Related Research Reports from UnivDatos Market Insights

·        Continuous Positive Airway Pressure (CPAP) Device Market to Reach US$ 4 Billion by 2026, Globally |CAGR: 9% |

·        Artificial Intelligence (AI) in Healthcare Market to Reach US$ 26.5 Billion by 2025, Globally |CAGR: 41%|

·        In-Vitro Diagnostics (IVDs) Market to reach US$ 98 Billion by 2025, Globally |CAGR: 5.24%|

·        Critical Care Equipment Market to Reach US$ 38 Billion by 2026 Globally |CAGR: 6%|